Molecular characterization of monovalent and multivalent hapten-protein conjugates for analysis of the antigen--antibody interaction.

We prepared a hapten-protein conjugate using (4-hydroxy-3-nitrophenyl)acetyl (NP) hapten and hen egg lysozyme (HEL) or bovine serum albumin (BSA) and defined hapten modification sites on the former protein based on results of reverse-phase high-performance liquid chromatography (HPLC) and mass spectrometric analyses performed after enzymatic digestion. The most reactive residue for aminoacetylation in HEL was found to be Lys33, and the second was Lys96 or Lys97. The homogeneous NP-HEL conjugates were purified by HPLC and used for examining the effect of hapten valence on the antigen-antibody interaction. We also examined the molecular nature of NP conjugates of BSA. Analysis using mass spectroscopy showed that the mass distribution of NP-BSA conjugates was limited, although it became broader with an increase in NP valence. Surface plasmon resonance biosensor measurements were employed in measuring antigen-antibody interactions. The results showed that the apparent binding avidity depends on hapten valence, hapten density, size of carrier proteins, and intrinsic binding affinity of the antibody.

N-terminal domain of eotaxin-3 is important for activation of CC chemokine receptor 3.

Eotaxin-3 belongs to the CC chemokine family, and specifically recognizes CC chemokine receptor (CCR) 3 that is expressed on eosinophils, basophils and helper T type 2 cells. The three-dimensional structure of eotaxin-3 determined by nuclear magnetic resonance has revealed that the N-terminal nine residues preceding the first cysteine comprise an unstructured domain, which is also observed in other chemokine molecules. In order to determine the function of the N-terminal domain of eotaxin-3, we constructed various N-terminal-deletion mutants, and then examined their binding and chemotactic activities toward eosinophils in vitro. Competitive binding studies showed that the binding affinity of truncated mutant toward CCR3 was almost the same as that of wild-type eotaxin-3 even though the N-terminal truncation involved the first through to the ninth residues. In contrast, the chemotactic activity gradually decreased with extension of the N-terminal deletion, and when the deletion extended to the eighth residue, the activity was not detected at all. Thus, the N-terminal nine residues are not critical for binding but the N-terminal eight residues are essential for activation of CCR3. The truncated eotaxin-3 proteins lacking the N-terminal eight or nine residues inhibited the chemotactic activity of chemokines that recognize CCR3. The truncated mutants can possibly be used for anti-allergic and anti-HIV-1 therapy.